Jazz's $1B SCLC drug fails combo trial, quashing hopes of quick full approval. But how much does it matter?
Lurbinectedin was looking like a great turnaround story for Spanish biotech PharmaMar. More than a year after the drug flopped in a Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
